Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

计划入组 900 人 · 首次发布于 2020 年 6 月 1 日

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

计划入组 719 人 · 首次发布于 2016 年 7 月 13 日

Gemini Symbicort pMDI

计划入组 615 人 · 首次发布于 2008 年 3 月 28 日

GEMINI-PSI

REVTx-300

GEM-104(Gemini Therapeutics)

Gemini Therapeutics, Inc.

United States

NHI-1

United States

Xi'an No.1 Hospital

China

Vanda Pharmaceuticals Submits BLA for Imsidolimab to Treat Rare Generalized Pustular Psoriasis

Sanofi's Tolebrutinib Shows Promise in Non-Relapsing Secondary Progressive MS

FDA Approves First Eye Drops for Presbyopia Treatment, Offering Alternative to Reading Glasses